Immune Cell Infiltration in Primary and Recurrent Glioblastoma, IDH ‐Wild Type: Validation of an Immunohistochemistry‐Based Scoring System for Research and Clinical Practice
APMIS · 2026
DOI: 10.1111/apm.70143 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift APMIS, 2026. Verfasst von Leontien Verlinden und 7 weiteren Autor:innen. Beteiligte Einrichtung: Experimental Pathology (EXPA), Vrije Universiteit Brussel (VUB), Brussels, Belgium. Hauptthemen laut MEDLINE: Glioblastoma, Immunohistochemistry, Brain Neoplasms, Lymphocytes, Tumor-Infiltrating. Die Arbeit nennt 40 Literaturangaben.
Abstract (Originalsprache)
Significant heterogeneity in the immune microenvironment of Glioblastoma, IDH‐wildtype (GBM), has been reported, necessitating a standardized approach to evaluate immune infiltration in the context of emerging immunotherapies. To address this, we developed and validated a standardized immunohistochemistry‐based scoring system for quantifying immune cell infiltration in formalin‐fixed, paraffin‐embedded (FFPE) tissue. Paired primary and recurrent GBM specimens from 20 adult patients were labeled for CD3, CD8, CD45, CD68, and PD‐1, and scored across six anatomical regions, including intra‐ and peritumoral, meningeal, and normal brain areas. The scoring system demonstrated excellent interrater (ICC = 0.932) and intrarater (ICC = 0.953) reliability. CD68+ and CD45+ cells were most numerous across all regions. CD3+ and CD8+ cells concentrated more in the perivascular area rather than within the parenchyma. No significant differences in immune infiltration were observed between primary and recurrent GBM. Cox proportional‐hazards analysis showed worse survival with higher CD8+ and CD45+ infiltration in primary GBM, and higher CD45+ and CD68+ infiltration in recurrent GBM. In conclusion, we propose a feasible, cost‐efficient, and robust method to assess immune infiltration on FFPE material, enabling standardized comparison of inflammation, with applications for ongoing clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Experimental Pathology (EXPA), Vrije Universiteit Brussel (VUB), Brussels, Belgium.
- Department of Pathology, Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium.
- Vrije Universiteit Brussel (VUB), Brussels, Belgium.
- Department of Neurosurgery, Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium.
- Department of Medical Oncology, Laboratory for Medical and Molecular Oncology (LMMO), Translational Oncology Research Center (TORC), Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Brusse…
Zitieren
APA
Verlinden, L., Michotte, A., Cools, W., Locy, H., Forsyth, R., Duerinck, J., Neyns, B., & Brock, S. (2026). Immune Cell Infiltration in Primary and Recurrent Glioblastoma, IDH ‐Wild Type: Validation of an Immunohistochemistry‐Based Scoring System for Research and Clinical Practice. APMIS. https://doi.org/10.1111/apm.70143
Vancouver
Verlinden L, Michotte A, Cools W, Locy H, Forsyth R, Duerinck J, et al. Immune Cell Infiltration in Primary and Recurrent Glioblastoma, IDH ‐Wild Type: Validation of an Immunohistochemistry‐Based Scoring System for Research and Clinical Practice. APMIS. 2026. doi:10.1111/apm.70143
BibTeX
@article{Verlinden2026,
author = {Verlinden, Leontien and Michotte, Alex and Cools, Wilfried and Locy, Hanne and Forsyth, Ramses and Duerinck, Johnny and Neyns, Bart and Brock, Stefanie},
title = {Immune Cell Infiltration in Primary and Recurrent Glioblastoma, IDH ‐Wild Type: Validation of an Immunohistochemistry‐Based Scoring System for Research and Clinical Practice},
journal = {APMIS},
year = {2026},
doi = {10.1111/apm.70143}
}
EUVIMED